RPE

OpRegen® Data Update to Be Featured at 2021 American Academy of Ophthalmology Annual Meeting in Presentation by Michael S. Ip, M.D.

Retrieved on: 
Tuesday, October 26, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Optical, Health, Clinical Trials, Safety, Bruch, AMD, VAC2, Surgeon, European Medicines Agency, U.S. Securities and Exchange Commission, Compte rendu, OCT, American Academy of Ophthalmology, RPE, Twitter, Gene, Lineage Cell Therapeutics, AAO, Therapy, David Geffen School of Medicine at UCLA, American Academy, Retinal pigment epithelium, History of the University of California, Los Angeles, Incidence, Blood, Severe cognitive impairment, Security (finance), Food, Infection, Injury, Ernest, Annual report, Company, EDT, Degenerative disease, Association, Department, Human embryonic stem cells clinical trials, Large-cell lung carcinoma, SEC, NYSE American, Geographic atrophy, Method, University, Cancer, TASE, FDA, Drusen, Forward-looking statement, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmaceutical industry, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

, Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.

Key Points: 
  • , Professor, Department of Ophthalmology at the David Geffen School of Medicine at the University of California - Los Angeles.
  • The American Academy of Ophthalmology is the worlds largest association of eye physicians and surgeons.
  • The mission of the American Academy of Ophthalmology is to protect sight and empower lives by serving as an advocate for patients and the public, leading ophthalmic education, and advancing the profession of ophthalmology.
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.

Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit

Retrieved on: 
Tuesday, October 19, 2021
ALS, IND, Visual impairment, Tissue, Death, PUFA, Cell damage, Investigational New Drug, Western world, FA, Reading, Oxidative stress, GLOBE, Patient, University, INAD, Animal, RT001, LA, Retinal pigment epithelium, Demonstration, GA, AMD, Infantile neuroaxonal dystrophy, Collection, Amyotrophic lateral sclerosis, Time, DHA, University of Pennsylvania, Vicious Circle, RATS, Disease, Drusen, LPO, Time-invariant system, Retina, Dihydroxy-E,Z,E-PUFA, Geographic atrophy, Inflammation, Central retinal artery occlusion, Degenerative disease, Dry, Injection, Â, Severe cognitive impairment, RPE, Lipid peroxidation, LOS, Program, Research, Stress (linguistics), PSP, Therapy, Vaccine, Pharmaceutical industry, Dietary supplement

LOS ALTOS, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases, today announced that positive results from preclinical studies of RT011, the second compound to emerge from the company’s novel technology platform, are being reported in multiple oral presentations at the 2nd Annual Dry AMD Therapeutic Development Summit. Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD. Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals. The conference, which is being conducted in a virtual format, is being held October 19-21, 2021.

Key Points: 
  • Findings to be presented demonstrate that RT011, which is being developed as an oral therapy for the treatment of dry age-related macular degeneration (AMD), provided dose-dependent protection in animal models of oxidative damage implicated in dry AMD.
  • Importantly, study results showed that animals treated with RT011 experienced preservation of retinal cells, photoreceptors, and visual function relative to control animals.
  • The company expects to file an Investigational New Drug (IND) application for RT011 in the first half of 2022 and initiate first-in-human clinical studies in dry AMD soon thereafter.
  • Study results demonstrated that animals treated with RT011 experienced decreasing levels of retinal damage with increasing tissue concentrations of RT011.

Outlook on the Choroidal Neovascularization Global Market to 2026 - by Product Type, Type of Diagnosis, Treatment Type, Application and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 30, 2021
Health, General Health, Retina, Adoption, OCT, Bruch, Histoplasmosis, Fluorescein angiography, Sterilization, FA, Choroid, Diagnosis, Retinal pigment epithelium, Angioid streaks, Solution, RPE, Distortion, Patient, Choroidal neovascularization, Angiography, PDT, Indocyanine green, Industry, ARMD, ICG, Growth, Prevalence, Disease, Risk, VEGF, COVID-19, Research, CNV, Blood, R, Investment, Coronavirus, Pharmaceutical industry, Potash

Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.

Key Points: 
  • Its symptoms include lipid exudation, subretinal blood and fluid, and distortion, waviness and black spots in the central vision.
  • How has the global choroidal neovascularization market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global choroidal neovascularization market?
  • What is the structure of the global choroidal neovascularization market and who are the key players?

Promising New OpRegen® Clinical Data Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
Thursday, September 30, 2021
Research, Surgery, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Optical, Science, OCT, Therapy, Geographic atrophy, Bruch, Cohort, Lineage Cell Therapeutics, AMD, Population, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Clinical trial, University, Cell, Safety, VAC2, SEC, Food, Injury, European Medicines Agency, Multimedia, CEI, Infection, NYSE American, Incidence, Association, Retina, Degenerative disease, Severe cognitive impairment, Patient, Annual report, U.S. Securities and Exchange Commission, FDA, Cancer, Method, Company, LLC, Large-cell lung carcinoma, Forward-looking statement, Drusen, Time, Compte rendu, Diagnosis, Retinal pigment epithelium, Security (finance), RPE, Visual acuity, TASE, Trial of the century, NCSS, Blood, Treatment effect, Pharmaceutical industry, Dentistry, Medical imaging, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

This is an exciting time for the OpRegen program, the participating investigative sites, and for patients suffering from dry AMD.

Key Points: 
  • This is an exciting time for the OpRegen program, the participating investigative sites, and for patients suffering from dry AMD.
  • The efficacy findings presented today are both statistically significant as well as clinically important, stated Christopher D. Riemann, M.D.
  • Prior clinical data readouts were mostly descriptive and lacked enough patients and post-treatment follow-up to allow for detailed statistical analyses.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .

Inflammasome Therapeutics’ Kamuvudines Continue to Show Promise for Future Treatment – and Potentially a Cure – for Blindness in Seniors

Retrieved on: 
Thursday, September 30, 2021
Science, Other Science, Research, Optical, General Health, Health, Clinical Trials, Other Health, Retina, Rest, Geographic atrophy, Severe cognitive impairment, Degenerative disease, Intravitreal injection, University, Ageing, III, RPE, AMD, Population, Toxicity, A-DNA, Bill, CEO, MS, Center, Disease, Boehringer Ingelheim, HIV disease progression rates, Human, View, Research, Bill & Melinda Gates Foundation, Cell, Pharmaceutical industry

It has been previously reported that Alu RNA is over expressed in the retinas of individuals with this condition.

Key Points: 
  • It has been previously reported that Alu RNA is over expressed in the retinas of individuals with this condition.
  • The paper confirms that in human eyes Alu RNA/cDNA conversion triggers inflammasome activity and resulting retinal cell death.
  • Additionally, we continue to strengthen the body of peer-reviewed science that demonstrates NRTIs and Kamuvudines ability to inhibit inflammasome activation.
  • Dr. Ashton said that Inflammasome plans to bring one or more of its Kamuvudines into the clinic in 2022.

Data From Ongoing Clinical Trial Continues to Demonstrate a Single Administration of OpRegen® Can Provide Anatomical and Functional Improvements in Patients With Dry AMD With Geographic Atrophy

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Lineage Cell Therapeutics, OCT, Degenerative disease, Infection, Patient, Retinal pigment epithelium, Institute, Adult, Large-cell lung carcinoma, Visual acuity, Blood, Cohort, Geographic atrophy, Program, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Forward-looking statement, Antibody, Health, NYSE American, Bruch, U.S. Securities and Exchange Commission, Annual report, Severe cognitive impairment, Growth, Central retinal artery occlusion, Cancer, RPE, Drusen, Optical coherence tomography, Food, Therapy, Security (finance), Cell, Incidence, FDA, VAC2, Retina, TASE, Injury, HIV disease progression rates, Safety, Human, SEC, Method, European Medicines Agency, Autumn, Technology, Company, Multimedia, History, Compte rendu, AMD, Atrophy, Pharmaceutical industry, Medical imaging, Silviculture, Dentistry, Hospital

While competing efforts are focused on reducing the growth rate of geographic atrophy, Lineage has reported several patients whose areas of atrophy have stabilized or reduced in size.

Key Points: 
  • While competing efforts are focused on reducing the growth rate of geographic atrophy, Lineage has reported several patients whose areas of atrophy have stabilized or reduced in size.
  • Importantly, all three of the patients exhibiting restoration had confirmed historic growth rate in these areas and these data have been collected using multiple imaging modalities.
  • We are extremely pleased that our data is moving in a positive direction with each interim update we provide.
  • We will continue to collect follow up data and work towards a meeting with FDA to discuss key aspects of our program.

Opregen® Data Update Will Be Featured at 54th Annual Retina Society Meeting in Podium Presentation by Christopher D. Riemann, M.D.

Retrieved on: 
Monday, September 13, 2021
Health, Genetics, Clinical Trials, Pharmaceutical, Optical, Biotechnology, European Medicines Agency, Drusen, Therapy, Association, Food, Incidence, Cell, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lineage Cell Therapeutics, Injury, University, Degenerative disease, VAC2, Clinical trial, Retina, TASE, Patient, Infection, Company, Retinal pigment epithelium, NYSE American, Bruch, Spinal cord injury, CEI, Severe cognitive impairment, Safety, Large-cell lung carcinoma, Blood, The Ritz-Carlton Hotel Company, Diagnosis, Cancer, AMD, Geographic atrophy, Method, RPE, Pharmaceutical industry, OpRegen, Age-Related Macular Degeneration, Lineage Cell Therapeutics, Inc., OPREGEN, AGE-RELATED MACULAR DEGENERATION, LINEAGE CELL THERAPEUTICS, INC.

The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.

Key Points: 
  • The Retina Society was founded in 1968 exclusively for educational and scientific purposes concerning the diagnosis, care and treatment of diseases and injuries to the retina.
  • For more information on the Retina Society or its annual scientific meeting, please visit https://www.retinasociety.org/ or follow the association on Twitter @RetinaSociety .
  • The first 3 cohorts enrolled only legally blind patients with Best Corrected Visual Acuity (BCVA) of 20/200 or worse.
  • The fourth cohort enrolled 12 better vision patients (BCVA from 20/65 to 20/250 with smaller mean areas of GA).

Respiratory Protective Equipment Market Report 2021 - Global Industry Trends, Share, Size, Growth, Opportunity and Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Chemicals, Plastics, Other Manufacturing, Manufacturing, Articles, Protective gear, Academic disciplines, Respiratory protective equipment, Safety, Human activities, Occupational safety and health, Personal protective equipment, Respirator, RPE

The "Respiratory Protective Equipment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Respiratory Protective Equipment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory protective equipment market reached a value of US$ 8.08 Billion in 2020.
  • The respiratory protective equipment (RPE) refers to a kind of personal protective equipment (PPE) that safeguards the wearer from inhaling hazardous substances, dust particles and gases in the air.
  • What is the structure of the global respiratory protective equipment market and who are the key players?

Beyond Pulse Partners with SVEXA to Boost Data Metrics Capabilities to Help Coaches and Enlighten Young Athletes

Retrieved on: 
Wednesday, June 2, 2021
Physical exercise, Articles, Human behavior, Applied sciences, Exercise physiology, Rating of perceived exertion, Scales, Sports science, Exertion, Youth sports, RPE, Pulse

BP also will track various subjective ratings, including session Rate of Perceived Exertion (RPE) of athletes through data collected from simple daily surveys.

Key Points: 
  • BP also will track various subjective ratings, including session Rate of Perceived Exertion (RPE) of athletes through data collected from simple daily surveys.
  • By doing that, we believe it leads to transformational experiences for young athletes," said Marc-Andre Maillet, CEO and co-founder, Beyond Pulse.
  • "At SVEXA, our goal is to unlock the power of data both for athletes and their coaches," said Mikael Mattsson, CEO, SVEXA.
  • Designed by coaches for coaches, Beyond Pulse exists to create a better youth sports culture, by helping coaches be better teachers and leaders.

Global Respiratory Protective Equipment Markets, 2020-2026 - Adoption of Stringent Regulatory Policies & Massive Industrial Growth in Asia-Pacific and Middle East & Africa

Retrieved on: 
Wednesday, April 14, 2021
Articles, Occupational safety and health, Protective gear, Academic disciplines, Euthenics, Respiratory protective equipment, Safety, Respirator, Personal protective equipment, RPE

b'DUBLIN, April 14, 2021 /PRNewswire/ -- The "Global Respiratory Protective Equipment Market: Growth, Trends, Competitive Landscape, and Forecasts" report has been added to ResearchAndMarkets.com\'s offering.\nThe global respiratory protective equipment market is expected to grow at a CAGR of around 4.6% during 2020-2026.\nThe respiratory protective equipment (RPE) is kind of personal protective equipment (PPE) that protects the wearer from inhaling harmful substances, dust particles and toxic gases in the air.\nIt consists of various filtering devices, masks and breathing apparatuses, which cover the nose, mouth or the entire face to filter out the contaminants.

Key Points: 
  • b'DUBLIN, April 14, 2021 /PRNewswire/ -- The "Global Respiratory Protective Equipment Market: Growth, Trends, Competitive Landscape, and Forecasts" report has been added to ResearchAndMarkets.com\'s offering.\nThe global respiratory protective equipment market is expected to grow at a CAGR of around 4.6% during 2020-2026.\nThe respiratory protective equipment (RPE) is kind of personal protective equipment (PPE) that protects the wearer from inhaling harmful substances, dust particles and toxic gases in the air.\nIt consists of various filtering devices, masks and breathing apparatuses, which cover the nose, mouth or the entire face to filter out the contaminants.
  • It also includes half/full mask respirators, helmets, hoods, visors, escape/airline respirators and supplied air respirators.\nThe global respiratory protective equipment market market report elucidates key industry trends, industry dynamics along with the quantitative analysis of the report.\nThe report presents a clear picture of the global respiratory protective equipment market by segmenting the market based on product type, filter type, end user, and region.
  • We believe that this report will aid the professionals and industry stakeholders in making informed decision.\n'